Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)

NCT01712217 is registered in ClinicalTrials.gov with Astex Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01712217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01712217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
Lead sponsor
Astex Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
October 31, 2012
Completion date
May 16, 2017
Enrollment
220 (actual)
Sites
65

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer(nsclc)